Kirk W Johnson - JoVE Visualize

Showing results (51-60 of 63) with videos related to

Pageof 7

Sort By:

Journal of Medicinal Chemistry|June 27, 2003

Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amidesSandra A Filla, Brian M Mathes, Kirk W Johnson, et al.

Diabetes|February 28, 2003

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivoDavid B Ring, Kirk W Johnson, Erik J Henriksen, et al.

Brain, Behavior, and Immunity|October 22, 2008

Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)Mark R Hutchinson, Susannah S Lewis, Benjamen D Coats, et al.

Journal of Peptide Science : an Official Publication of the European Peptide Society|March 18, 2011

Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonistsLiang Zeng Yan, Kirk W Johnson, Emily Rothstein, et al.

British Journal of Pharmacology|August 17, 2019

Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditanEloísa Rubio-Beltrán, Alejandro Labastida-Ramírez, Kristian A Haanes, et al.

Pain|April 21, 2025

Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318Lisa M Broad, Jeffrey G Suico, P Kellie Turner, et al.

Pain|September 5, 2006

Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic painErin D Milligan, Evan M Sloane, Stephen J Langer, et al.

Bioorganic & Medicinal Chemistry Letters|December 3, 2016

Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headacheMaria-Jesus Blanco, Dana R Benesh, James A Knobelsdorf, et al.

The Journal of Pharmacology and Experimental Therapeutics|May 13, 2006

Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivoBrianne Weiss, Andrew Alt, Ann Marie Ogden, et al.

Journal of Medicinal Chemistry|October 11, 2017

Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3Allan S Wagman, Rustum S Boyce, Sean P Brown, et al.

Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:

Pageof 7

Journal of Medicinal Chemistry|June 27, 2003

Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amidesSandra A Filla, Brian M Mathes, Kirk W Johnson, et al.

Diabetes|February 28, 2003

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivoDavid B Ring, Kirk W Johnson, Erik J Henriksen, et al.

Brain, Behavior, and Immunity|October 22, 2008

Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)Mark R Hutchinson, Susannah S Lewis, Benjamen D Coats, et al.

Journal of Peptide Science : an Official Publication of the European Peptide Society|March 18, 2011

Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonistsLiang Zeng Yan, Kirk W Johnson, Emily Rothstein, et al.

British Journal of Pharmacology|August 17, 2019

Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditanEloísa Rubio-Beltrán, Alejandro Labastida-Ramírez, Kristian A Haanes, et al.

Pain|April 21, 2025

Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318Lisa M Broad, Jeffrey G Suico, P Kellie Turner, et al.

Pain|September 5, 2006

Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic painErin D Milligan, Evan M Sloane, Stephen J Langer, et al.

Bioorganic & Medicinal Chemistry Letters|December 3, 2016

Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headacheMaria-Jesus Blanco, Dana R Benesh, James A Knobelsdorf, et al.

The Journal of Pharmacology and Experimental Therapeutics|May 13, 2006

Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivoBrianne Weiss, Andrew Alt, Ann Marie Ogden, et al.

Journal of Medicinal Chemistry|October 11, 2017

Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3Allan S Wagman, Rustum S Boyce, Sean P Brown, et al.

Pageof 7